Leukocyte Rho kinase activity and serum cystatin C affect cardiovascular events in acute coronary syndrome.

Objective: This study was designed to investigate the effects of leukocyte Rho kinase activity and serum Cystatin C (Cys C) on cardiovascular events in patients with acute coronary syndrome (ACS). Methods: A total of 48 patients with ST-segment elevation myocardial infarction (STEMI), 23 patients with non-ST-segment elevation myocardial infarction (NSTEMI), 25 patients with unstable angina (UA) and 20 patients with no-acute coronary syndrome as control from January 2017 to June 2018 in Tianyou Hospital affiliated to Wuhan University of Science and Technology were selected in this study. Western blot was used to detect the leukocyte Rho kinase activity and Elisa kit was used to measure serum Cys C. Univariate and multivariate analysis were used to analyze the influencing factors of cardiovascular events in ACS patients. Results: The activity of leukocyte Rho kinase and serum Cys C were gradually reduced in the STEMI, NSTEMI and UA patients, but all significantly higher than that in No-ASC patients, and there was a positive correlation between leukocyte Rho kinase activity and serum Cys C in ACS patients (r = 0.516,P < .001). The activity of leukocyte Rho kinase was positively correlated with the levels of serum TNF-alpha (r = 0.634,P < .001), IL-6 (r = 0.578,P < .001), IL-8 (r = 0.582,P < .001) in ACS patients, and the level of Cys C was positively correlated with the levels of serum TNF-alpha (r = 0.634,P < .001), IL-6 (r = 0.578,P < .001), IL-8 (r = 0.582,P < .001) in ACS patients. Univariate and multivariate analysis showed that the leukocyte Rho kinase activity (HR = 2.994, 95%CI = 1.328-6.054,P < .0001) and the levels of serum Cys C (HR = 1.692, 95%CI = 1.028-2.124,P < .0001) were independent influencing factors of cardiovascular events in ACS patients. Conclusion: The leukocyte Rho kinase activity and serum Cystatin C are high in acute coronary syndrome patients, and are the independent influencing factors of cardiovascular events in ACS patients.